News release via Canada NewsWire, Toronto 416-863-9350
Attention Business Editors:
PreMD Inc. Provides Corporate Update
TORONTO, Oct. 3 /CNW/ - Predictive medicine company PreMD Inc. (TSX: PMD;
Amex: PME) is pleased to announce an update on the company's 510(k)
application to the US Food and Drug Administration (FDA) and involvement in
upcoming conferences.
On Wednesday, October 3, 2007, Dr. Brent Norton, president and chief
executive officer of PreMD, will present at BioContact Quebec, a leading
annual biopharmaceutical conference. The conference takes place from October
3-5, 2007, in Quebec City.
PreMD is preparing the information recently requested by the FDA. In
September, PreMD held discussions with the FDA in order to clarify the
necessary information required to obtain an expanded regulatory claim for the
company's POC skin cholesterol test. At this time, pursuant to multiple
communications with the FDA and its marketing partner, PreMD anticipates
submitting the final response in the coming weeks, within the required
timeframe.
PreMD is also involved in several upcoming conferences to be held in Q4
2007. The company will be presenting and exhibiting at the ValueRich Small-Cap
Financial Expo on October 18, 2007, in New York. PreMD will also be exhibiting
at the Association of Home Underwriters (AHOU) 2007 Annual Conference in
Toronto from October 21-24, 2007, on its PREVU(x) LT product. On November 5-7,
2007, PreMD will be presenting at the Acumen BioFin Rodman & Renshaw 9th
Annual Healthcare Conference in New York.
PreMD is also pleased to announce the presentation date of the scientific
abstract entitled 'Increased Skin Cholesterol Identifies Individuals at
Increased Cardiovascular Risk: The Predictor of Advanced Subclinical
Atherosclerosis (PASA) Study' at the American Heart Association Conference.
The AHA Scientific Sessions conference takes place November 2-7, 2007 in
Orlando, Florida and the PASA presentation will take place in the morning
session on Monday, November 5, 2007.
About PreMD
PreMD Inc. is a leader in predictive medicine, dedicated to developing
rapid, non-invasive tests for the early detection of life-threatening
diseases. PreMD's cardiovascular products, currently branded as PREVU(x) Skin
Cholesterol Test, will be marketed and distributed by AstraZeneca. The
company's cancer tests include ColorectAlert(TM), LungAlert(TM) and a breast
cancer test. PreMD's head office is located in Toronto, Ontario and its
research and product development facility is at McMaster University in
Hamilton, Ontario. For more information about PREVU(x), please visit
www.prevu.com.
This press release contains forward-looking statements. These statements
involve known and unknown risks and uncertainties, which could cause the
company's actual results to differ materially from those in the
forward-looking statements. Such risks and uncertainties include, among
others, the successful development or marketing of the company's products, the
competitiveness of the company's products if successfully commercialized, the
lack of operating profit and availability of funds and resources to pursue R&D
projects, the successful and timely completion of clinical studies, product
liability, reliance on third-party manufacturers, the ability of the company
to take advantage of business opportunities, uncertainties related to the
regulatory process, and general changes in economic conditions.
In addition, while the Company routinely obtains patents for its products
and technology, the protection offered by the Company's patents and patent
applications may be challenged, invalidated or circumvented by our competitors
and there can be no guarantee of our ability to obtain or maintain patent
protection for our products or product candidates.
Investors should consult the Company's quarterly and annual filings with
the Canadian and U.S. securities commissions for additional information on
risks and uncertainties relating to the forward-looking statements. Investors
are cautioned not to rely on these forward-looking statements. PreMD is
providing this information as of the date of this press release and does not
undertake any obligation to update any forward-looking statements contained in
this press release as a result of new information, future events or otherwise.
(x) Trademark
%SEDAR: 00007927E %CIK: 0001179083
/For further information: Ron Hosking, Vice-President Finance and CFO,
Tel: (416) 222-3449 ext. 24, Email: rhosking(at)premdinc.com; Michelle Rabba,
Manager, Corporate Communications, Tel: (416) 222-3449 ext 25, Email:
mrabba(at)premdinc.com/
(PMD. PME)
CO: PreMD Inc.
CNW 09:01e 03-OCT-07
